Xencor Announces Upcoming Change to Board of Directors
Xencor (NASDAQ: XNCR), a clinical-stage biopharmaceutical company focused on developing engineered antibodies for cancer and other serious diseases, has announced an upcoming change to its Board of Directors. Dagmar Rosa-Bjorkeson, who has served as a director since 2019, will not seek reelection at the 2025 Annual Meeting of Stockholders. Rosa-Bjorkeson plans to pursue another business opportunity.
Xencor is actively recruiting additional Board members with complementary skillsets. The company's CEO, Bassil Dahiyat, Ph.D., expressed gratitude for Rosa-Bjorkeson's contributions to the Board and its audit and nominating and governance committees, particularly her strategic guidance in advancing programs and rebalancing the company's portfolio.
Xencor (NASDAQ: XNCR), una società biofarmaceutica in fase clinica focalizzata sullo sviluppo di anticorpi ingegnerizzati per il cancro e altre malattie gravi, ha annunciato un prossimo cambiamento nel suo Consiglio di Amministrazione. Dagmar Rosa-Bjorkeson, che è stata direttrice dal 2019, non si candiderà per la rielezione alla Riunione Annuale degli Azionisti del 2025. Rosa-Bjorkeson prevede di perseguire un'altra opportunità lavorativa.
Xencor sta attivamente reclutando ulteriori membri del Consiglio con competenze complementari. Il CEO dell'azienda, Bassil Dahiyat, Ph.D., ha espresso gratitudine per i contributi di Rosa-Bjorkeson al Consiglio e ai comitati di audit, nomina e governance, in particolare per la sua guida strategica nel far avanzare i programmi e nel riequilibrare il portafoglio dell'azienda.
Xencor (NASDAQ: XNCR), una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de anticuerpos ingenierizados para el cáncer y otras enfermedades graves, ha anunciado un próximo cambio en su Junta Directiva. Dagmar Rosa-Bjorkeson, quien ha sido directora desde 2019, no buscará la reelección en la Reunión Anual de Accionistas de 2025. Rosa-Bjorkeson planea perseguir otra oportunidad de negocio.
Xencor está reclutando activamente miembros adicionales para la Junta con habilidades complementarias. El CEO de la compañía, Bassil Dahiyat, Ph.D., expresó su gratitud por las contribuciones de Rosa-Bjorkeson a la Junta y a sus comités de auditoría, nominación y gobernanza, en particular por su orientación estratégica en el avance de los programas y el reajuste del portafolio de la compañía.
Xencor (NASDAQ: XNCR)는 암 및 기타 중병을 위한 설계된 항체 개발에 초점을 맞춘 임상 단계의 생물 제약 회사로, 이사의 변경을 발표했습니다. Dagmar Rosa-Bjorkeson은 2019년부터 이사로 재직해 왔으며, 2025년 주주 총회에서 재선거에 나서지 않을 것이라고 밝혔습니다. Rosa-Bjorkeson은 다른 사업 기회를 추구할 계획입니다.
Xencor는 보완적인 기술 세트를 갖춘 추가 이사들을 적극적으로 모집하고 있습니다. 회사의 CEO인 Bassil Dahiyat, Ph.D.는 Rosa-Bjorkeson이 이사회의 감사 및 지명 위원회에 기여한 것에 대해 감사의 뜻을 표했으며, 특히 프로그램을 진전시키고 회사의 포트폴리오를 재조정하는 데 있어 그녀의 전략적 지침에 감사를 표했습니다.
Xencor (NASDAQ: XNCR), une société bio-pharmaceutique en phase clinique axée sur le développement d'anticorps ingénierisés pour le cancer et d'autres maladies graves, a annoncé un prochain changement au sein de son Conseil d'Administration. Dagmar Rosa-Bjorkeson, qui est membre du conseil depuis 2019, ne cherchera pas à être réélue lors de l'Assemblée Générale des Actionnaires de 2025. Rosa-Bjorkeson prévoit de poursuivre une autre opportunité professionnelle.
Xencor recrute activement des membres supplémentaires pour son Conseil avec des compétences complémentaires. Le PDG de l'entreprise, Bassil Dahiyat, Ph.D., a exprimé sa gratitude pour les contributions de Rosa-Bjorkeson au Conseil et à ses comités d'audit, de nomination et de gouvernance, en particulier pour ses conseils stratégiques dans l'avancement des programmes et le rééquilibrage du portefeuille de l'entreprise.
Xencor (NASDAQ: XNCR), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von konstruierten Antikörpern für Krebs und andere schwere Krankheiten konzentriert, hat eine bevorstehende Änderung im Vorstand bekannt gegeben. Dagmar Rosa-Bjorkeson, die seit 2019 als Direktorin tätig ist, wird sich nicht um eine Wiederwahl bei der Jahreshauptversammlung 2025 bewerben. Rosa-Bjorkeson plant, eine andere Geschäftsmöglichkeit zu verfolgen.
Xencor ist aktiv auf der Suche nach zusätzlichen Vorstandsmitgliedern mit komplementären Fähigkeiten. Der CEO des Unternehmens, Bassil Dahiyat, Ph.D., drückte seine Dankbarkeit für die Beiträge von Rosa-Bjorkeson zum Vorstand und zu den Ausschüssen für Prüfung, Nominierung und Governance aus, insbesondere für ihre strategische Anleitung bei der Weiterentwicklung von Programmen und der Umstrukturierung des Portfolios des Unternehmens.
- Proactive approach to Board composition with ongoing recruitment of members with complementary skillsets
- Loss of a Board member with 4 years of experience in the company
“On behalf of Xencor's Board of Directors and management team, I want to thank Dagmar for her many contributions to our Board and our audit and nominating and governance committees,” said Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor. “Dagmar provided strategic guidance as we have advanced programs and rebalanced our portfolio, and we wish her well in all future endeavors.”
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and other serious diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241004953837/en/
Charles Liles
cliles@xencor.com
(626) 737-8118
For Media:
Cassidy McClain
Inizio Evoke
cassidy.mcclain@inizioevoke.com
(619) 694-6291
Source: Xencor, Inc.
FAQ
When will Dagmar Rosa-Bjorkeson leave Xencor's (XNCR) Board of Directors?
How long has Dagmar Rosa-Bjorkeson served on Xencor's (XNCR) Board of Directors?
What is Xencor (XNCR) doing to address the upcoming Board vacancy?
What committees did Dagmar Rosa-Bjorkeson serve on at Xencor (XNCR)?
